PRKG1 (Protein Kinase cGMP-Dependent 1) encodes the cyclic GMP-dependent protein kinase 1 (PKG1), a serine/threonine kinase that mediates the effects of cyclic GMP (cGMP) on various cellular processes. PKG1 is a key effector of the nitric oxide (NO)-cGMP signaling pathway and plays important roles in neuronal function, synaptic plasticity, and cardiovascular regulation. Dysregulation of PKG1 signaling has been implicated in multiple neurodegenerative conditions.
| Property |
Value |
| Symbol |
PRKG1 |
| Full Name |
Protein Kinase cGMP-Dependent 1 |
| Aliases |
PKG, PKG1a, PKG1b, cGK, cGK1 |
| Chromosome |
10q21.3 |
| Gene ID |
5590 |
| Category |
Signal Transduction |
| Protein Class |
Serine/Threonine Kinase |
¶ Protein Structure and Function
PKG1 exists in two alternatively spliced isoforms:
- PKG1α: Higher affinity for cGMP, predominant in cerebellum
- PKG1β: Lower cGMP affinity, more widely expressed
The protein consists of:
- N-terminal regulatory domain with cGMP binding sites
- Catalytic kinase domain
- Dimerization domain
PKG1 is activated by binding of cGMP, which relieves autoinhibition and activates the kinase domain. Key activators include:
- Nitric oxide (NO) → soluble guanylate cyclase (sGC) → cGMP
- Atrial natriuretic peptide (ANP) → particulate guanylate cyclase → cGMP
- cGMP analogs (8-Br-cGMP, 8-pCPT-cGMP)
In neurons, PKG1 regulates:
- Synaptic plasticity: PKG is required for long-term potentiation (LTP) and long-term depression (LTD)
- Gene expression: Phosphorylates transcription factors including CREB
- Ion channel function: Modulates NMDA receptor activity and calcium channels
- Dendritic spine morphology: Regulates spine formation and maintenance
- Axon guidance: Controls growth cone dynamics
Multiple lines of evidence link PKG1 dysregulation to AD pathogenesis:
- Amyloid-β effects: Aβ oligomers impair NO-cGMP signaling, reducing PKG1 activation and contributing to synaptic dysfunction
- Tau pathology: PKG1 can phosphorylate tau, potentially affecting its aggregation and toxicity
- Memory deficits: PKG inhibitors impair memory, while PKG activators enhance cognitive function
PKG1 signaling is altered in PD models and may affect:
- Dopaminergic neuron survival: NO-cGMP-PKG signaling influences neuronal viability
- Mitochondrial function: PKG regulates mitochondrial dynamics and biogenesis
- Neuroinflammation: PKG modulates microglial activation and inflammatory responses
¶ Stroke and Vascular Dementia
Given its role in vascular function, PKG1 is relevant to vascular cognitive impairment:
- Regulates cerebral blood flow
- Controls blood-brain barrier integrity
- Mediates ischemic preconditioning
PKG1 is a potential therapeutic target:
- PKG activators: Cinaciguat and similar compounds for vascular cognitive impairment
- PDE5 inhibitors (e.g., sildenafil): Increase cGMP levels, indirectly activating PKG
- NO donors: Enhance cGMP production
Clinical trials are investigating PDE5 inhibitors for dementia-related cognitive decline.
Key questions remain:
- How does PKG1 dysregulation contribute to specific neurodegenerative processes?
- Can PKG-targeted therapies improve cognitive function in AD/PD?
- What are the isoform-specific roles in neurons?